Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies.
INTRODUCTION We explored the impact of the Sociodemographic Index (SDI) on the efficacy/safety of tofacitinib and adalimumab in patients with rheumatoid arthritis (RA). METHODS This post hoc analysis used data from phase 2/3/3b/4 studies of patients with RA receiving tofacitinib 5 or 10 mg twice daily (BID), adalimum...